Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity by unknown
BriefDefinitive Report
INTERLEUKIN 5 ENHANCES INTERLEUKIN 2-MEDIATED
LYMPHOKINE-ACTIVATED KILLER ACTIVITY
BY TOMOKAZU AOKI, HARUHIKO KIKUCHI, SHIN-ICHI MIYATAKE,
YOSHIFUMI ODA, KOICHI IWASAKI, TOSHIKI YAMASAKI,
TATSUO KINASHI,` AND TASUKU HONJO`
From the Department of Neurosurgery and 'Medical Chemistry, Faculty ofMedicine,
Kyoto University, Sakyo-ku, Kyoto 606, Japan
After 3-6 d ofin vitro incubation with IL-2, human PBL and mouse splenic lym-
phocytes become cytotoxic to a variety of tumor cells, including not only NK-sensitive,
but also NK-resistant tumor cells(1-3). These IL-2-dependent lymphocytes consist
ofa heterogeneous population ofeffectors (4-6). They also show non-MHC-restricted
cytotoxicity, which has been referred to as the lymphokine-activated killer (LAK)
phenomenon (2).
On the other hand, murine IL-5 (mIL-5) was previously described as a T
cell-replacing factor (TRF) (7, 8) and as a B cell growth factor II (9) based on its
induction of proliferation and Ig secretion by activated B cells. This lymphokine
has been shown to exert several other effects, including the induction of growth and
differentiation of eosinophils from bone marrow stem cells (10), the induction of
differentiation of peanut agglutinin-positive (PNA+) thymocytes into CTL (11), and
the induction of mIL-2-R expression on both splenic B cells and PNA+ thymocytes
(12, 13).
In this study, we examined the effect of mIL-5 on the in vitro induction of LAK
activity as a basic study for modified adoptive immunotherapy.
Materials and Methods
Mice.
￿
Male C57BL/6 mice, 6-8 wk old, were supplied by the Shizuoka Animal Center
(Shizuoka, Japan).
Tumors.
￿
203 glioma is a malignant glioma cell line originally induced by 20-methylchol-
antherene from the C57BL/6 strain. The tumor cells were maintained in a monolayer form
in tissue culture with Dulbecco's modified MEM (Nissui, Japan) supplemented with 10%
heat-inactivated FCS (Gibco Laboratories, Grand Island, NY) and antibiotics (penicillin G,
200 U/ml; streptomycin sulfate, 50 Kg/ml). Methylcholantherene-induced mastocytoma (P815),
originating from DBA/2 mice, and Moloney leukemia virus-induced T celllymphoma (YAC-1),
originating from A/Sn mice, were maintained in RPMI 1640 (Nissui, Japan) with 10% heat-
inactivated FCS and antibiotics.
Lymphokines.
￿
Human rIL-2 (TGP-3; 4.2 x 104 U/mg protein) was kindly supplied by
Takeda Chemical Industry, Ltd., Osaka, Japan.
rmIL-5 was the culture supernatant ofX63-Ag8.653 myeloma cells transfected with mIL-5
complementary DNA (14, 15). Culture supernatant (SN) (1,200 U/ml) was filtered and ali-
quots were stored at -70°C. Activity was determined by polyclonal IgM plaque-forming
cell (PFC) assay using TRFresponding BCLI cells (16). This culture SN contained no IL-1,
IL-2, IL-3, IL-4, IL-6, IL-7, or CSF (data not shown). Control culture SN was collected
from the original myeloma cell (X63-Ag8-653).
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Generation ofLAK Cells.
￿
Spleens were removed aseptically and crushed with the hub of
a syringe in RPMI 1640. Spleen cells were incubated with mIL-5 at a concentration of 2
x 106 cells/ml for 3 d in the presence of IL-2 in RPMI 1640 with 10% heat-inactivated FCS
and antibiotics. The culture was performed in 5-ml wells of a 6-well plate (Corning Glass
Works, Corning, NY). The cells were harvested, washed twice, and used as effectors.
Cytotoxicity Assay.
￿
A 4-h "Cr release assay in round-bottomed microtiter plates (Corning
Glass Works) was used to measure cytotoxicity. Target cellswere labeled with 0.1 mCi S'Cr
(Amershatn Corp., Arlington Heights, IL) for 60 min at 37°C. Effectors were coincubated
with the targets at various E/T ratios for 4 h at 37°C in humidified air with 5%a C02. The
radioactive SNs were harvested and counted with a gamma counter. The cytotoxic activity
was calculated from the average of triplicate cultures as: percent of cytolysis = 100x (ex-
perimental release-spontaneous release)/(maximum release-spontaneous release). Sponta-
neous release was determined by adding culture medium only to the target cells and max-
imum release was counted in detergent. All determinations in each experimentwere performed
in triplicate.
Results
The Effect of rIL-5 on the Induction ofLAK Cells.
￿
Freshly isolated spleen cells were
incubated with IL-2, rIL-5, or a combination ofIL-2 and rIL-5. As shown in Fig. 1,
rIL-5 enhanced IL-2-induced LAK activity, although rIL-5 alone induced no cyto-
toxic activity. Control SN obtained from X63-Ag8.653 myelorna cells did not show
such enhancement (data not shown). Freshly isolated spleen cells showed slight cy-
totoxicity against YAC-1, but little cytotoxicity against P815 and 203-glioma (data
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￿
rIL-5 enhances rIL-2-mediated LAK activity. C57BL/6 mouse splenocytes were cul-
tured at 2 x 106 cells/ml in 5 ml of complete medium containing rIL-2 (1 U/ml) and/or rIL-5
(50 U/ml). After 3 d, effectors were tested for cytotoxicity against 5'Cr-labeled tumor cells in
a 4-h assay: Control values represent the killer activity ofeffectors cultured in complete medium
without any lymphokines. Results are presented as the means of at least three experiments.Discussion
The present study demonstrates that mIL-5 enhances the LAK activity in the
presence of IL-2, though mIL-5 alone can not induce killer activity (Fig. 1). We
also found that in vitro the cell numbers are greater from cultures containing IL-2
plus mIL-5 than those containing IL-2 alone (data not shown). As mIL-5 induces
the expression of IL-2-R on both splenic B cells and PNA+ thymocytes (12, 13), it
may also induce the expression ofIL-2-R on LAK cells. Although mIL-5 alone can
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not shown). Spleen cells cultured without lymphokines for 3 d were ineffective in
lysing YAC-1, P815, and 203-glioma.
TheEffect ofrIL-5ontheInduction ofLAKActivity Depends on the Concentration ofIL-2.
IL-2 mediated LAKcell activity isalso dependent on IL-5 concentration. To deter-
mine the optimal concentration ofIL-2 or rIL-5 to obtain the maximum cytotoxic
activity, double titration experiments were carried out. In Fig. 2, these killer activi-
ties showdose dependency at IL-2 concentrations from 0.01 to 10 U/ml and at rIL-5
concentrations from 0.01 to 100 U/ml.
TheEffectsofVarious Time Schedules ofAdministration ofIL-2 and rIL-5 on theInduction
ofLAKActivity. As shown in Fig. 3, rIL-5 alone did not show killer activity when
IL-2 was not present from the onset ofculture (Fig. 3,jand k). IfIL-2 was present
from the onset ofculture, however, rIL-5 enhanced LAK activity, even when added
24-48 h after culture initiation (Fig. 3, h and a). Finally, the presence of IL-2 for
thefirst 24 or48 h andrIL-5 during thelast 48 or 24h, respectively, didnot enhance
LAK activity (Fig. 3, dande). These results suggest that rIL-5 actson the late stage
of the LAK induction in the presence of IL-2.
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FIGURE 2.
￿
Generation of LAK activity. Dose-response cytotoxic activity by rIL-5 and rIL-2.
C57BL/6 mouse splenocytes were cultured at various concentrations ofrIL-5 andrIL-2 for3 d.
Cytotoxicactivities againstYAC-1, P815, and203-Glioma were measured at an E/Tratioof20:1 .
All determinations in each experiment were performed in triplicate.586
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Effect of various time sched-
ules of administration ofrIL-5 and rIL-2
on LAKinduction. C57BL/6mousespleno-
cyteswere cultured. rIL-5(25U/ml)or rIL-
2 (1 U/ml) was present in the culture for
limitedperiods as indicated. After 3 d, cy-
totoxicactivities against YAC-1 and P815
were measured at an E/Tratioof20:1 . All
determinations in each experiment were
performed in triplicate. (
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not induce killer activity, some mechanisms involving IL-5-R probably may aug-
ment IL-2 signal transduction pathways.
mIL-5 may act on the late stage of LAK induction in the presence of IL-2. As
shown in Fig. 3, c, h, and i, ifIL-2 is present from the onset of culture, mIL-5 en-
hances LAKactivity, evenwhen mIL-5 is addedat thelate stage ofculture. IfmIL-5
is present from the onset ofculture, however, killer activity is not so enhanced, even
when IL-2 is added at the late stage (Fig. 3, j and k). Hence, it might be possible
that IL-2 activates precursor cells in the first stage, and mIL-5 augments the acti-
vated precursor cells. Moreover, this effect cannot take place in the absence ofIL-2
(Fig. 3, f and g).
Mule et al. (17) found that mIL-4 alone induces killer activity as well as IL-2-
mediated killer activity. mIL-5, on the other hand, enhances IL-2-mediated killer
activity, but mIL-5 alone does not induce the killer activity. These results suggest
that themechanismby which LAK activity isaugmented bymIL-5 is different from
that of mIL-4.
Unlike IL-2, mIL-4haslittle capacity to generate LAK activity frommouse PBL,
whereas both lymphokines induce this activity from splenocytes (17). Whether or
not mIL-5 and IL-2 similarly generate LAK activity from mouse PBL remains to
be determined.
Hergen et al. (18) found that human IL-4 blocks IL-2-generated LAK activity.
The reason for the discrepancy between human and mouse IL-4 is unclear. Apart
from the possibility that the ability of IL-4 to block the induction of LAK activity
is speciesrestricted, itmightbe possible thatmouse spleen cellscontain alreadyacti-AOKI ET AL.
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vated precursor cells. Hergen et al. (18) found IL-4 inhibits IL-2-induced LAK ac-
tivity in spleen cells.
It would be interesting, for the purpose of adoptive immunotherapy, to see whether
human IL-5 also enhances IL-2-induced LAK cell activity in PBL or not.
Summary
IL-5 expresses various biologic effects on several types of lymphocytes, including
B cells, eosinophils, and T cells. We demonstrated that the incubation of resting
splenocytes from C57BL/6 mice in murine rIL-5 enhances IL-2-mediated lymphokine-
activated killer (LAK) activity against various tumor cells. IL-5 alone, however, does
not induce killer activity. IL-2-mediated LAK activity increases in proportion to
the dose of IL-5 . During the late phase of the culture period, IL-5 seems to have
some effect on the induction of IL-2-mediated LAK activity. We expect that IL-5
will prove useful for adoptive immunotherapy.
Receivedforpublication 24 March 1989 and in revisedform 4 May 1989.
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